OA
TEVA icon

Oxbow Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Oxbow Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-181,587
Closed -$1.37M – 256
2022
Q2 		$1.37M Buy
181,587
+7,080
+4% +$61.7K 0.19% 86
2022
Q1 		$1.64M Buy
+174,507
New +$1.46M 0.16% 87
2017
Q3 		– Sell
-6,428
Closed -$214K – 247
2017
Q2 		$214K Buy
+6,428
New +$199K 0.04% 212
2017
Q1 		– Sell
-96,285
Closed -$3.49M – 274
2016
Q4 		$3.49M Buy
+96,285
New +$3.84M 0.44% 64
2014
Q2 		– Sell
-40,695
Closed -$2.15M – 225
2014
Q1 		$2.15M Hold
40,695
– – 0.32% 77
2013
Q4 		$1.63M Hold
40,695
– – 0.23% 95
2013
Q3 		$1.54M Buy
40,695
+2,475
+6% +$96.5K 0.25% 87
2013
Q2 		$1.5M Buy
+38,220
New +$1.49M 0.26% 76

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Oxbow Advisors's TEVA Position: Q3 2022 in Review

Oxbow Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 181,587 shares — an estimated $1.37M sold.

Oxbow Advisors first reported a position in TEVA in Q2 2013 and held it in 8 quarters. The position peaked at $3.49M in Q4 2016. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • Oxbow Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Oxbow Advisors sold 181,587 Teva Pharmaceuticals shares in Q3 2022, an estimated $1.37M.
  • Oxbow Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Oxbow Advisors's Teva Pharmaceuticals position peaked at $3.49M in Q4 2016.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on Oxbow Advisors's 13F filing for Q3 2022, filed 3 Nov 2022.